# First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

> **NCT07700160** · PHASE1,PHASE2 · RECRUITING · sponsor: **VelaVigo Bio Inc** · enrollment: 230 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** VBC108

## Key facts

- **NCT ID:** NCT07700160
- **Lead sponsor:** VelaVigo Bio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2029-07-07
- **Final completion:** 2029-09-17
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700160, "First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*